ExoZymes (EXOZ): Unlocking Hard-to-Scale Molecules with AI-Driven, Cell-Free Biomanufacturing

About this episode

Michael Heltzen discusses ExoZymes' innovative approach to biomanufacturing and its implications for scalability in synthetic biology.

Send us Fan Mail ExoZymes (NASDAQ: EXOZ) CEO Michael Heltzen joins Tim Gerdeman and Robert Sassoon in this episode of the WTR Small-Cap Spotlight podcast to discuss the company’s AI-driven, cell-free biomanufacturing platform and how it aims to overcome longstanding scalability challenges in synthetic biology. The conversation covers the scientific differentiation of its “exozyme” enzyme engineering approach, the commercial strategy behind its lead programs in metabolic health (NCT) and non-i...

People in this episode

Hosts: Tim Gerdeman, Robert Sassoon

Guest: Michael Heltzen

Topics covered

• AI-driven biomanufacturing
• synthetic biology
• enzyme engineering
• metabolic health
• scalability challenges

Keywords

• ExoZymes
• AI
• biomanufacturing
• synthetic biology
• enzyme engineering
• metabolic health
• scalability

Mentioned in this episode

Organizations: ExoZymes, NASDAQ, synthetic biology

More episodes of WTR Small-Cap Spotlight

• Pineapple Financial (PAPL): AI Tools and Tokenization: How a Canadian Fintech Is Modernizing the Mortgage Brokerage Market · June 11, 2026 · 18 min
• eGain Corporation (EGAN): Turns Messy Enterprise Data into Trusted AI Answers · June 10, 2026 · 22 min
• Mobilicom (MOB): CEO Details Why Mobilicom’s Secure Comm System is the Heart and Soul of Drones and Robots · June 10, 2026 · 32 min
• ZJK Industrial (ZJK): Precision Parts at the Heart of AI, EVs, and High-Tech Manufacturing · June 9, 2026 · 22 min
• LiveOne (LVO): The AT&T Deal, B2B Streaming Strategy, and Why Every Platform Needs an Audio Network · June 4, 2026 · 37 min
• CIRCULAR ECONOMY: Investing in SAF, CCUS and Waste-to-Value (PART 2 – CCUS) · June 4, 2026 · 52 min